Alkermes (ALKS) Operating Income (2010 - 2026)
Alkermes (ALKS) posted quarterly Operating Income of $18.4 million for Q2 2026, down 80.26% year-over-year from $93.0 million in Q2 2025, and up 138.01% quarter-over-quarter from -$48.3 million in Q1 2026.
Alkermes (ALKS) Operating Income (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Operating Income for 17 consecutive years, with $18.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Operating Income fell 80.26% year-over-year to $18.4 million; the TTM figure through Jun 2026 stood at $117.3 million (down 68.67% YoY), while the FY2025 annual figure was $254.0 million, down 39.63% from the prior year.
- Operating Income rose to $18.4 million in Q2 2026 per ALKS's latest filing, from -$48.3 million in the prior quarter.
- Across five years, Operating Income topped out at $281.3 million in Q2 2023 and bottomed at -$60.6 million in Q3 2022.
- Historically, Operating Income has averaged $58.5 million across 5 years, with a median of $56.4 million in 2023.
- Annual changes were most pronounced in 2022 — Operating Income sank 879.39% — and 2023, when it soared 916.29%.
- Alkermes' Operating Income stood at $115.6 million in 2022, then slumped by 52.74% to $54.6 million in 2023, then jumped by 197.79% to $162.7 million in 2024, then slumped by 64.29% to $58.1 million in 2025, then slumped by 68.41% to $18.4 million in 2026.
- Business Quant data shows ALKS's Operating Income at $18.4 million in Q2 2026, -$48.3 million in Q1 2026, and $58.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | -231.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 837.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 1.26 Bn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 330.80 Mn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 6.30 Mn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 151.50 Mn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 248.00 Mn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.54 Bn | 397.90 Mn | 18.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.35 Mn |
| Mar 31, 2026 | -48.28 Mn |
| Dec 31, 2025 | 58.10 Mn |
| Sep 30, 2025 | 89.08 Mn |
| Jun 30, 2025 | 92.98 Mn |
| Mar 31, 2025 | 13.79 Mn |
| Dec 31, 2024 | 162.69 Mn |
| Sep 30, 2024 | 104.76 Mn |
| Jun 30, 2024 | 109.88 Mn |
| Mar 31, 2024 | 43.31 Mn |
| Dec 31, 2023 | 54.63 Mn |
| Sep 30, 2023 | 89.19 Mn |
| Jun 30, 2023 | 281.27 Mn |
| Mar 31, 2023 | -10.97 Mn |
| Dec 31, 2022 | 115.59 Mn |
| Sep 30, 2022 | -60.64 Mn |
| Jun 30, 2022 | -34.46 Mn |
| Mar 31, 2022 | -26.59 Mn |
| Dec 31, 2021 | 129.42 Mn |
| Sep 30, 2021 | -19.66 Mn |